Mycoflor Injectable, Florfenicol (D:C.I) 30 % Soluton for Injection

Main information

  • Trade name:
  • Mycoflor Injectable, Florfenicol (D:C.I) 30 % Soluton for Injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Mycoflor Injectable, Florfenicol (D:C.I) 30 % Soluton for Injection
    Hungary
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • florfenicol
  • Therapeutic area:
  • Cattle, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0385/001
  • Authorization date:
  • 26-10-2011
  • EU code:
  • UK/V/0385/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:December2011

AN:00749/2010

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Mycoflor300mg/mlsolutionforinjectionforpigs

Florfenicol

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains

Activesubstance:

Florfenicol.300mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

SolutionforInjection

Clear,lightyellowtoyellowsolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Pigs.

4.2 Indicationsforuse,specifyingthetargetspecies

Pigs:Treatmentofacuteoutbreaksofrespiratorydiseasecausedbystrainsof

ActinobacilluspleuropneumoniaeandPasteurellamultocidasusceptibleto

florfenicol

4.3 Contraindications

Donotuseinadultboarsintendedforbreedingpurposes.

Donotadministertoanimalswithknownhypersensitivitytoflorfenicolortoany

oftheexcipientsoftheproduct

Donotuseincaseofknownresistancetoflorfenicol

Donotadministerintravenously

Refertosection4.11

4.4 Specialwarningsforeachtargetspecies

Donotexceedtherecommendedtreatmentdoseortherecommendedduration

oftreatment

Issued:December2011

AN:00749/2010

Page2of5

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Theproductshouldonlybeusedinpigletsoflessthan2kgafterabenefit:risk

assessmentbyaveterin arysurgeon’.

Theproductshouldbeusedinconjunctionwithsusceptibilitytestingandtake

intoaccountofficialandlocalantimicrobialpolicies.

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

Thestoppermustbecleanedbeforeremovingeachdose.Useadry,sterile

syringeandneedle.

Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Careshouldbetakentoavoidaccidentalself-injection.Incaseofself-

injection,seekmedicaladviceimmediatelyandshowthepackageleaflet

orthelabeltothephysician.

Avoiddirectcontactwithskin,mouthandeyes.Ifeyeexposureoccurs,

flusheyesimmediatelywithcleanwater.Ifskinexposureoccurs,wash

theaffectedareawithcleanwater.Ifaccidentalingestionoccurs,rinse

themouthwithplentyofwaterandseekmedicaladviceimmediately.

Washhandsafteruse.

Peoplewithknownhypersensitivitytoflorfenicolshouldavoidcontact

withtheproduct.

4.6Adversereactions(frequencyandseriousness)

Pigs

Commonlyobservedadverseeffectsaretransientdiarrhoeaand/orperi-anal

andrectalerythema/oedemawhichmayaffect50%oftheanimals.These

effectscanbeobservedforoneweek.

Transientswellinglastingupto5daysmaybeobservedatthesiteofinjection.

Inflammatorylesionsattheinjectionsitemaybeseenforupto28days.

Underfieldconditionsapproximately30%oftreatedpigspresentedwithpyrexia

C)associatedwitheithermoderatedepressionormoderatedyspneaa

weekormoreafteradministrationoftheseconddose.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryspecieshavenotproducedanyevidenceofteratogenicor

foetotoxiceffects.Safetyduringpregnancyandlactationhasnotbeen

investigatedinthetargetspecies.Useonlyaccordinglytothebenefit/risk

assessmentbytheresponsibleveterinarian.

Issued:December2011

AN:00749/2010

Page3of5

4.8Interactionwithothermedicinalproductsandotherformsof

interaction

Nodataavailable.

4.9 Amountstobeadministeredandadministrationroute

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

Thevialcannotbebroachedmorethan25times.

PIGS

IMinjectionof15mg/kgBW(1ml/20kg)intotheneckmuscletwice48hour

apart.

Thevolumeadministeredperinjectionsiteshouldnotexceed3ml.

Itisrecommendedtotreatanimalsintheearlystagesofdiseaseandto

evaluatetheresponsetotreatmentwithin48hoursafterthesecondinjection.If

clinicalsignsofrespiratorydiseasepersist48hoursafterthelastinjection,

treatmentshouldbechangedusinganotherformulationoranotherantibiotic

andcontinueduntilclinicalsignshaveresolved.

4.10Overdose (symptoms, emergency procedures, antidotes), if

necessary

Inswine,afteradministrationof3timestherecommendeddoseormorea

reductioninfeeding,hydrationandweightgainhasbeenobserved.After

administrationof5timestherecommendeddoseormorevomitinghasalso

beennoted.

4.11Withdrawalperiod(s)

Pigs:

Meatandoffal:18days

5. PHARMACOLOGICALPROPERTIES

Pharmacoterapeuticgroup:Antibacterialsforsystemicuse,amphenicols,

Florfenicol

ATCvetcode:QJ01BA90.

5.1 Pharmacodynamicproperties

FlorfenicolisasyntheticbroadspectrumantibioticeffectiveagainstmostGram-

positiveandGram-negativebacteriaisolatedfromdomesticanimals.

Florfenicolactsbyinhibitingproteinsynthesisattheribosomallevelandis

bacteriostatic.Laboratorytestshaveshownthatflorfenicolisactiveagainstthe

mostcommonlyisolatedbacterialpathogensinvolvedinbovinerespiratory

diseasewhichincludeMannheimiahaemolytica,Pasteurellamultocidaand,

Histophilussomni.

Issued:December2011

AN:00749/2010

Page4of5

Florfenicolisconsideredtobeabacteriostaticagent,butinvitrostudiesof

florfenicoldemonstratebactericidalactivityagainstMannheimiahaemolytica,

Pasteurellamultocida,HistophilussomniandActinobacilluspleuropneumoniae.

Acquiredresistancetoflorfenicolismediatedbyeffluxpumpresistance

associatedwithaflogene.Crossresistancewithchloramphenicoland

thiamphenicolcanoccur

5.2 Pharmacokineticparticulars

PIGS

Afterintramuscularadministrationoftherecommendeddoseof15mg/kg,

maximumserumconcentrationof2.48µg/mlisreachedafter2.0hoursandthe

concentrationsdepletewithaterminalhalf-lifeof14.9hours.Serum

concentrationsdropbelow1µg/ml,theMIC90forthetargetporcinepathogens,

12-24hoursfollowingIMadministrationFlorfenicolconcentrationsachievedin

lungtissuereflectplasmaconcentration,withalung:plasmaconcentrationratio

ofapproximately1.Afteradministrationtopigsbytheintramuscularroute,

florfenicolisrapidlyexcreted,primarilyinurine.Theflorfenicolisextensively

metabolised

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

N-Methylpyrrolidone

Glycerolformal

6.2Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmust

notbemixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale2years

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days

6.4.Specialprecautionsforstorage

Storethebottleintheoutercartoninordertoprotectfromdirectsunlight.

6.5Natureandcompositionofimmediatepackaging

Vialsizes:100and250ml

-ColourlessTypeIIglassvialsclosedwithbromobutylrubberclosuresandan

aluminiumcap.

Issued:December2011

AN:00749/2010

Page5of5

-Polypropylenevialsclosedwithbromobutylrubberclosuresandanaluminium

cap.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

SPVeterinaria,S.A.

Ctra.Reus

VinyolsKm4.1Aptdo.60

43330Riudoms

Spain

8. MARKETINGAUTHORISATIONNUMBER

Vm36967/4000

9. DATEOFFIRSTAUTHORISATION

21December2011

10. DATEOFREVISIONOFTHETEXT

December2011

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Veterinaryprescription.

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

31-7-2018

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

FDA - U.S. Food and Drug Administration

1-6-2018

Demulen 30 birth control pills: Packages containing broken or chipped pills

Demulen 30 birth control pills: Packages containing broken or chipped pills

Pfizer Canada Inc. has notified Health Canada that it has received complaints of broken or chipped pills involving Demulen 30, a prescription birth control pill. Health Canada has previously communicated on similar issues involving two other brands of birth control pills. Health Canada continues to remind women to check their packages of birth control pills and to report problems if they see them. If you notice anything unusual in the package, such as missing or damaged pills, you should return the packa...

Health Canada

19-4-2018

March 30, 2018: KC Paramedic Indicted for Stealing Fentanyl, Morphine from Ambulances

March 30, 2018: KC Paramedic Indicted for Stealing Fentanyl, Morphine from Ambulances

March 30, 2018: KC Paramedic Indicted for Stealing Fentanyl, Morphine from Ambulances

FDA - U.S. Food and Drug Administration

19-4-2018

March 30, 2018: Counterfeit Cigarette Smuggler Sentenced to Prison

March 30, 2018: Counterfeit Cigarette Smuggler Sentenced to Prison

March 30, 2018: Counterfeit Cigarette Smuggler Sentenced to Prison

FDA - U.S. Food and Drug Administration

19-4-2018

March 30, 2018: Lynn Man Sentenced to Over 10 Years in Prison for Role in Counterfeit Steroid Conspiracy

March 30, 2018: Lynn Man Sentenced to Over 10 Years in Prison for Role in Counterfeit Steroid Conspiracy

March 30, 2018: Lynn Man Sentenced to Over 10 Years in Prison for Role in Counterfeit Steroid Conspiracy

FDA - U.S. Food and Drug Administration

23-9-2016

The IMA will be closed from noon on Friday 30 September

The IMA will be closed from noon on Friday 30 September

The IMA will be closed from noon on Friday 30 September due to a staff meeting. If necessary call +354 899 6962.

IMA - Icelandic Medicines Agency

3-6-2014

Amendment of executive order on euphoriant substances 30 May 2014

Amendment of executive order on euphoriant substances 30 May 2014

On 30 May 2014, the substances below were included in annex 1 of executive order no. 557 of 31 May 2011 on euphoriant substances issued by the Danish Ministry of Health.

Danish Medicines Agency

21-11-2018

Osurnia (Elanco GmbH)

Osurnia (Elanco GmbH)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7842 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/003753/T/0010

Europe -DG Health and Food Safety

17-9-2018

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction.   Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept.

FDA - U.S. Food and Drug Administration

3-8-2018

Scandonest and associated names

Scandonest and associated names

Scandonest and associated names (Active substance: mepivacaine) - Community Referrals - Art 30 - Commission Decision (2018)5380 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-30/1455

Europe -DG Health and Food Safety

30-5-2018

The FDA will accept submissions from June 1, 2018, through Sept. 30, 2018, and intends to announce the selected applicants in November 2018.  #FDAInnovationChallenge

The FDA will accept submissions from June 1, 2018, through Sept. 30, 2018, and intends to announce the selected applicants in November 2018. #FDAInnovationChallenge

The FDA will accept submissions from June 1, 2018, through Sept. 30, 2018, and intends to announce the selected applicants in November 2018. #FDAInnovationChallenge

FDA - U.S. Food and Drug Administration

30-5-2018

Descovy (Gilead Sciences Ireland UC)

Descovy (Gilead Sciences Ireland UC)

Descovy (Active substance: emtricitabine / tenofovir alafenamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3471 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4094/T/30

Europe -DG Health and Food Safety

29-5-2018

Osurnia (Elanco Europe Ltd)

Osurnia (Elanco Europe Ltd)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Yearly update - Commission Decision (2018)3406 of Tue, 29 May 2018

Europe -DG Health and Food Safety